Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program

References

• Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
   PubMed Web of Science ®Google Scholar
• Carr AJ, Gibson B, Robinson PG. Measuring quality of life: is quality of life determined by expectations or experience? BMJ. 2001;322(7296):1240–1243.
   PubMed Web of Science ®Google Scholar
• White MA, O’Neil PM, Kolotkin RL, et al. Gender, race, and obesity-related quality of life at extreme levels of obesity. Obes Res. 2004;12(6):949–955.
   PubMedGoogle Scholar
• Zorjan S, Schienle A. Temporal dynamics of mental imagery, craving and consumption of craved foods: an experience sampling study. Psychol Health. 2022;1–17. https://doi.org/10.1080/08870446.2022.2033239
   Google Scholar
• Emmer C, Bosnjak M, Mata J. The association between weight stigma and mental health: a meta-analysis. Obes Rev. 2020;21(1):e12935.
   PubMed Web of Science ®Google Scholar
• Ul-Haq Z, Mackay DF, Fenwick E, et al. Meta-analysis of the association between body mass index and health-related quality of life among children and adolescents, assessed using the pediatric quality of life inventory index. J Pediatr. 2013;162(2):280–286.e1.
   PubMed Web of Science ®Google Scholar
• Kolotkin RL, Andersen JR. A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life. Clin Obes. 2017;7(5):273–289.
   PubMed Web of Science ®Google Scholar
• Stephenson J, Smith CM, Kearns B, et al. The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study. BMC Public Health. 2021;21(1):1990.
   PubMed Web of Science ®Google Scholar
• Chlabicz M, Dubatowka M, Jamiolkowski J, et al. Subjective well-being in non-obese individuals depends strongly on body composition. Sci Rep. 2021;11(1):21797.
   PubMed Web of Science ®Google Scholar
• Mikkola TM, Kautiainen H, von Bonsdorff MB, et al. Body composition and changes in health-related quality of life in older age: a 10-year follow-up of the Helsinki Birth Cohort Study. Qual Life Res. 2020;29(8):2039–2050.
   PubMed Web of Science ®Google Scholar
• Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939–949.
   PubMed Web of Science ®Google Scholar
• Avila C, Holloway AC, Hahn MK, et al. An overview of links between obesity and mental health. Curr Obes Rep. 2015;4(3):303–310.
   PubMed Web of Science ®Google Scholar
• Kolotkin RL, Williams VSL, Ervin CM, et al. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clin Obes. 2019;9(3):e12310.
   PubMed Web of Science ®Google Scholar
• Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity (Silver Spring). 2009;17(5):941–964.
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Damms-Machado A, Betz C, et al. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life–a prospective study. Int J Obes (Lond). 2012;36(4):614–624.
   PubMed Web of Science ®Google Scholar
• Zawisza K, Tobiasz-Adamczyk B, Galas A, et al. Changes in body mass index and quality of life—population-based follow-up study COURAGE and COURAGE-POLFUS, Poland. Appl Res Qual Life. 2021;16(2):501–526.
   Web of Science ®Google Scholar
• Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188–1196.
   PubMed Web of Science ®Google Scholar
• Boswell RG, Kober H. Food cue reactivity and craving predict eating and weight gain: a meta-analytic review. Obes Rev. 2016;17(2):159–177.
   PubMed Web of Science ®Google Scholar
• Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci (Lond). 2013;124(4):231–241.
   PubMed Web of Science ®Google Scholar
• Sweeting AN, Hocking SL, Markovic TP. Pharmacotherapy for the treatment of obesity. Mol Cell Endocrinol. 2015;418 Pt 2:173–183.
   PubMedGoogle Scholar
• Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604.
   PubMed Web of Science ®Google Scholar
• Blomain ES, Dirhan DA, Valentino MA, et al. Mechanisms of weight regain following weight loss. ISRN Obes. 2013;2013:210524.
   PubMedGoogle Scholar
• Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–1061.
   PubMed Web of Science ®Google Scholar
• Rose F, Bloom S, Tan T. Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years. Expert Opin Drug Discov. 2019;14(11):1151–1159.
   PubMed Web of Science ®Google Scholar
• Bays H, Pi-Sunyer X, Hemmingsson JU, et al. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin. 2017;33(2):225–229.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Saxenda® highlights of prescribing information. 2014 [cited 2022 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf
   Google Scholar
• US Food and Drug Administration. Wegovy highlights of prescribing information. 2021 [cited 2022 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
   Google Scholar
• US Food and Drug Administration. Victoza® highlights of prescribing information. 2010 [cited 2022 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022341s035lbl.pdf
   Google Scholar
• US Food and Drug Administration. Ozempic® highlights of prescribing information. 2017 [cited 2022 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf
   Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984.
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
   PubMed Web of Science ®Google Scholar
• Garvey TW, Batterham RL, Bhatta M, et al. Two-year effect of semaglutide 2.4 mg vs placebo in adults with overweight or obesity: STEP 5. Abstract presented at the 39th Annual Meeting of the Obesity Society at ObesityWeek® [Oral 096]; 2021 Nov 1–5; Virtual 2021.
   Google Scholar
• Wharton S, Batterham RL, Bhatta M, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Abstract presented at the 39th Annual Meeting of the Obesity Society at ObesityWeek® [Oral 095]; 2021 Nov 1–5; Virtual 2021.
   Google Scholar
• Kolotkin RL, Crosby RD, Kosloski KD, et al. Development of a brief measure to assess quality of life in obesity. Obes Res. 2001;9(2):102–111.
   PubMedGoogle Scholar
• US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009 [cited 2022 Jan 24]. Available from: https://www.fda.gov/media/77832/download
   Google Scholar
• Kolotkin RL, Williams VSL, von Huth Smith L, et al. Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT). Clin Obes. 2021;11(5):e12477.
   PubMed Web of Science ®Google Scholar
• Maruish ME, editor. User’s manual for the SF-36v2 health survey. QualityMetric Inc. 3rd ed. Lincoln, RI: QualityMetric Inc; 2011.
   Google Scholar
• Ware JE Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol. 1998;51(11):903–912.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(Suppl 1):A16–A17.
   Google Scholar
• European Medicines Agency. Guideline on clinical evaluation of medicinal products used in weight management. 2016 [cited 2022 Aug 9]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-used-weight-management-revision-1_en.pdf
   Google Scholar
• US Food and Drug Administration. Guidance for industry developing products for weight management. 2007 [cited 2022 Jan 24]. Available from: https://www.fda.gov/media/71252/download
   Google Scholar
• Wharton S, Bjorner JB, Kushner RF, et al. AD12.08: Semaglutide 2.4 mg once weekly improves patient-reported outcome measures of physical functioning in adults with overweight or obesity in the STEP 1 trial. Obes Facts. 2021;14(Suppl 1):1–154. pg 52.
   Google Scholar
• Rubino D, Færch L, Meincke HH, et al. 84-OR: Semaglutide 2.4 mg improves health-related quality of life in adults with overweight/obesity and type 2 diabetes in the STEP 2 trial. Diabetes. 2021;70(Supplement 1):84–OR.
   Google Scholar
• Rubino DM, Bjorner JB, Kushner RF, et al. EP4-25: Beneficial effect of semaglutide 2.4 mg once weekly on patient-reported outcome measures of weight-related and health-related quality of life in adults with overweight or obesity in the STEP 1 trial. Obes Facts. 2021;14(Suppl 1):1–154. pg 118.
   Google Scholar
• Wharton S, Meincke HH, Kushner RF, et al. 85-OR: Semaglutide 2.4 mg improves patient reported outcome measures of physical functioning in adults with overweight/obesity and type 2 diabetes in the STEP 2 trial. Diabetes. 2021;70(Supplement 1):85–OR.
   Google Scholar
• Rubino D, Færch L, Meincke HH, et al. 84-OR: Semaglutide 2.4 mg improves health-related quality of life in adults with overweight/obesity and type 2 diabetes in the STEP 2 trial. Presentation at the 81st Scientific Sessions of the American Diabetes Association; 2021 June 25–29; Virtual 2021.
   Google Scholar
• Muennig P, Lubetkin E, Jia H, et al. Gender and the burden of disease attributable to obesity. Am J Public Health. 2006;96(9):1662–1668.
   PubMed Web of Science ®Google Scholar
• Audureau E, Pouchot J, Coste J. Gender-related differential effects of obesity on health-related quality of life via obesity-related comorbidities: a mediation analysis of a French nationwide survey. Circ Cardiovasc Qual Outcomes. 2016;9(3):246–256.
   PubMed Web of Science ®Google Scholar
• Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134(4):359–375.
   PubMed Web of Science ®Google Scholar
• Houston DK, Leng X, Bray GA, et al. A long-term intensive lifestyle intervention and physical function: the Look AHEAD Movement and Memory study. Obesity (Silver Spring). 2015;23(1):77–84.
   PubMed Web of Science ®Google Scholar
• Sharma A, Meincke H, Jensen C, et al. Continued semaglutide 2.4 mg once weekly improved health related quality of life in the STEP 4 trial. Abstract presented at the 39th Annual Meeting of the Obesity Society at ObesityWeek® [Oral 014]; 2021 Nov 1–5; Virtual 2021.
   Google Scholar
• Abraham SB, Abel BS, Rubino D, et al. A direct comparison of quality of life in obese and Cushing’s syndrome patients. Eur J Endocrinol. 2013;168(5):787–793.
   PubMed Web of Science ®Google Scholar
• Meule A. The psychology of food cravings: the role of food deprivation. Curr Nutr Rep. 2020;9(3):251–257.
   PubMedGoogle Scholar
• Myers CA, Martin CK, Apolzan JW. Food cravings and body weight: a conditioning response. Curr Opin Endocrinol Diabetes Obes. 2018;25(5):298–302.
   PubMedGoogle Scholar
• Martin CK, O’Neil PM, Pawlow L. Changes in food cravings during low-calorie and very-low-calorie diets. Obesity (Silver Spring). 2006;14(1):115–121.
   PubMed Web of Science ®Google Scholar
• Morin I, Bégin C, Maltais-Giguère J, et al. Impact of experimentally induced cognitive dietary restraint on eating behavior traits, appetite sensations, and markers of stress during energy restriction in overweight/obese women. J Obes. 2018;2018:4259389.
   PubMed Web of Science ®Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251.
   PubMed Web of Science ®Google Scholar
• Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–762.
   PubMed Web of Science ®Google Scholar
• Gibbons C, Blundell J, Tetens Hoff S, et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):581–588.
   PubMed Web of Science ®Google Scholar
• Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–1730.
   PubMed Web of Science ®Google Scholar
• Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017;8(3):511–519.
   PubMed Web of Science ®Google Scholar
• Willoughby D, Hewlings S, Kalman D. Body composition changes in weight loss: strategies and supplementation for maintaining lean body mass, a brief review. Nutrients. 2018;10(12):1876.
   PubMed Web of Science ®Google Scholar
• Correia de Faria Santarém G, de Cleva R, Santo MA, et al. Correlation between body composition and walking capacity in severe obesity. PLoS One. 2015;10(6):e0130268.
   PubMed Web of Science ®Google Scholar
• Hales SB, Schulte EM, Turner TF, et al. Pilot evaluation of a personalized commercial program on weight loss, health outcomes, and quality of life. Transl Behav Med. 2021;11(12):2091–2098.
   PubMed Web of Science ®Google Scholar
• Kolotkin RL, Gabriel Smolarz B, Meincke HH, et al. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clin Obes. 2018;8(1):1–10.
   PubMed Web of Science ®Google Scholar